ES2162257T3 - N-aminoalquildibenzofurancarboxamidas como ligandos especificos del subtipo de receptor de la dopamina. - Google Patents

N-aminoalquildibenzofurancarboxamidas como ligandos especificos del subtipo de receptor de la dopamina.

Info

Publication number
ES2162257T3
ES2162257T3 ES97908719T ES97908719T ES2162257T3 ES 2162257 T3 ES2162257 T3 ES 2162257T3 ES 97908719 T ES97908719 T ES 97908719T ES 97908719 T ES97908719 T ES 97908719T ES 2162257 T3 ES2162257 T3 ES 2162257T3
Authority
ES
Spain
Prior art keywords
alkyl
disorders
compounds
hydrogen
subtipe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97908719T
Other languages
English (en)
Inventor
Jun Yuan
Xi Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Application granted granted Critical
Publication of ES2162257T3 publication Critical patent/ES2162257T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA GENERAL (I), O A LAS SALES DE ADICION FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, DONDE: R 1 , R 2 , R 3 , R 4 SON I GUALES O DISTINTOS Y REPRESENTAN HIDROGENO, ALQUILO C 1 C6 , HALOGENO, HIDROXILO, AMINO, CIANO, NITRO, TRIFLUOROME TILO, TRIFLUOROMETOXI, ALCOXI C 1 - C 6 , O 2 CR'', - NHCOR'', - COR'', - SO M R'', DONDE R'' ES ALQUILO C 1 C 6 Y DONDE M ES 0, 1 O 2; O R 1 , R 2 , R 3 , R 4 REPRESENTAN INDEPENDIENTEMENTE - CONR'' M O - NR'' M , DONDE M ES 0, 1 O 2 Y R'' ES HIDROGENO O ALQUILO C SU B,1 - C 6 ; Y R REPRESENTA UN GRUPO AMINOALQUILO. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ALTERACIONES AFECTIVAS, COMO LA ESQUIZOFRENIA, DEPRESION, ENFERMEDAD DE ALZHEIMER, ALTERACIONES MOTORAS COMO EL PARKINSONISMO Y LA DISTONIA, Y OTRAS ALTERACIONES QUE SE DEBEN AL BLOQUEO DOPAMINERGICO, COMO EL ABUSO DE MEDICAMENTOS Y LAS ALTERACIONES COMPULSIVAS OBSESIVAS. ADEMAS, LOS COMPUESTOS DE LA INVENCION PUEDEN SER UTILES PARA EL TRATAMIENTO DE LOS EFECTOSSECUNDARIOS EXTRAPIRAMIDALES ASOCIADOS CON LA UTILIZACION DE AGENTES NEUROLEPTICOS CONVENCIONALES.
ES97908719T 1996-02-28 1997-02-26 N-aminoalquildibenzofurancarboxamidas como ligandos especificos del subtipo de receptor de la dopamina. Expired - Lifetime ES2162257T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/608,259 US5710274A (en) 1996-02-28 1996-02-28 N-aminoalkyldibenzofurancarboxamides; new dopamine receptor subtype specific ligands

Publications (1)

Publication Number Publication Date
ES2162257T3 true ES2162257T3 (es) 2001-12-16

Family

ID=24435715

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97908719T Expired - Lifetime ES2162257T3 (es) 1996-02-28 1997-02-26 N-aminoalquildibenzofurancarboxamidas como ligandos especificos del subtipo de receptor de la dopamina.

Country Status (9)

Country Link
US (2) US5710274A (es)
EP (1) EP0891354B1 (es)
JP (1) JP3176935B2 (es)
AT (1) ATE205493T1 (es)
AU (1) AU726310B2 (es)
CA (1) CA2248269A1 (es)
DE (1) DE69706660T2 (es)
ES (1) ES2162257T3 (es)
WO (1) WO1997031916A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
EA200100428A1 (ru) 1998-10-08 2001-10-22 Смитклайн Бичам Плс Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты)
US6506712B2 (en) 2001-05-21 2003-01-14 React, Llc Method of manufacturing a multifunctional additive and using the same
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
CN1948298B (zh) * 2006-11-09 2010-09-01 东南大学 一种多巴胺d3受体部分激动剂及其应用
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CA2690789C (en) 2007-06-15 2014-08-05 Amy Hauck Newman 4-phenylpiperazine derivatives with functionalized linkers as dopamine d3 receptor selective ligands and methods of use
JP5366269B2 (ja) 2007-09-14 2013-12-11 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換４−（アリル−ｘ−フェニル）−１ｈ−ピリジン−２−オン
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
CN101801930B (zh) * 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
US8785486B2 (en) * 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MX2011011962A (es) 2009-05-12 2012-02-28 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2).
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
SG10201402250TA (en) 2009-05-12 2014-07-30 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2552879T3 (es) 2010-11-08 2015-12-02 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EA201891617A3 (ru) 2014-01-21 2019-04-30 Янссен Фармацевтика Нв Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
US11299476B2 (en) 2016-03-14 2022-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof
CA3111785A1 (en) 2018-09-11 2020-03-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3 receptor selective antagonists/partial agonists and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903116A (en) * 1969-06-16 1975-09-02 Richardson Merrell Inc Bis-basic amides of dibenzofuran
US3867409A (en) * 1969-06-16 1975-02-18 Richardson Merrell Inc Bis-basic esters of dibenzofuran
US3751390A (en) * 1971-05-19 1973-08-07 Aldrich Chem Co Inc Substituted dibenzofuran
US4863921A (en) * 1988-04-27 1989-09-05 Rorer Pharmaceutical Corporation Dibenzofurancarboxamides and their pharmaceutical compositions and methods
EP0494140A4 (en) * 1989-09-27 1992-09-02 Rorer International (Holdings), Inc. Dibenzofurancarboxamides
MX9306311A (es) * 1992-10-13 1994-04-29 Smithkline Beecham Plc Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
US5395835A (en) * 1994-03-24 1995-03-07 Warner-Lambert Company Naphthalamides as central nervous system agents

Also Published As

Publication number Publication date
US5977367A (en) 1999-11-02
JP3176935B2 (ja) 2001-06-18
JPH11504947A (ja) 1999-05-11
EP0891354A1 (en) 1999-01-20
ATE205493T1 (de) 2001-09-15
WO1997031916A1 (en) 1997-09-04
DE69706660T2 (de) 2002-04-18
CA2248269A1 (en) 1997-09-04
AU726310B2 (en) 2000-11-02
DE69706660D1 (de) 2001-10-18
AU2055797A (en) 1997-09-16
US5710274A (en) 1998-01-20
EP0891354B1 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
ES2162257T3 (es) N-aminoalquildibenzofurancarboxamidas como ligandos especificos del subtipo de receptor de la dopamina.
ES2157565T3 (es) N-azacicloalquilalquildibenzotiofenocarboxamidas: ligandos especificos de un subtipo de receptor de la dopamina.
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
ES2282685T3 (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
BR9908084A (pt) Composto, processo para tratar um paciente afligido por algum distúrbio do sistema nervoso central e periférico, composição farmacêutica, e, uso de um composto
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
BR0007424A (pt) Composto, composição farmacêutica, método para o tratamento de depressão em um paciente necessitando do mesmo, e, processo para a preparação de um composto
PT96085A (pt) Processo para a preparacao de ciclo-hexanois substituidos como agentes do sistema nervoso central
SV1999000102A (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa. ref. pcs 9475 afae/bb.
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
PA8468501A1 (es) Compuestos heterociclicos como inhibidores de enzimas rotamasas
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
ES2165360T3 (es) Cicloalquenos y cicloalcanos 1,3-sustituidos como agentes del sistema nervioso central.
DE60014136D1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
BR0315837A (pt) Derivados de amida de ácido heteroaril-hexanóico como agentes imunomoduladores
NO176097C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte cykloheksener
BRPI0410613A (pt) preparação de quinoxalinas substituìdas a partir da dianlina com 2,3-diidróxi-1,4-dioxano
BR9906719A (pt) "n-óxidos de compostos heterocìclicos com atividade inibidora de tnf e de pde-iv"
AU2459897A (en) Novel n-aminoalkyl-1-biphenylenyl-2-carboxamides; new dopamine receptor subtype specific ligands
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
EA200200656A1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
EA200501053A1 (ru) Производные 1,2,4-триаминобензола, пригодные для лечения расстройств центральной нервной системы

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 891354

Country of ref document: ES